Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma

NCT01939899 ↗

Phase 2 Completed 29 enrolled Millennium Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as measured by overall response rate (ORR) in adult participants with relapsed and/or refractory follicular lymphoma (FL).

Timeline

Start: 2013-10-31
Primary completion: 2016-06-01
Completion: 2017-03-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ixazomib	Unknown	4 mg	Oral
Subject	Ixazomib	Unknown	5.3 mg	Oral
Subject	Ixazomib	Unknown	7 mg	Oral

Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma

Summary

Timeline

Drugs

Indications